Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial

BACKGROUND: The aim of this study was to investigate the antitumour activity, safety, and tolerability of pamiparib plus tislelizumab in patients with previously treated advanced solid tumours. METHODS: In this study, patients were enrolled into eight arms by tumour type. All received pamiparib 40 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedlander, Michael, Mileshkin, Linda, Lombard, Janine, Frentzas, Sophia, Gao, Bo, Wilson, Michelle, Meniawy, Tarek, Baron-Hay, Sally, Briscoe, Karen, McCarthy, Nicole, Fountzilas, Christos, Cervantes, Andres, Ge, Ruimin, Wu, John, Spira, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449784/
https://www.ncbi.nlm.nih.gov/pubmed/37474720
http://dx.doi.org/10.1038/s41416-023-02349-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449784/
https://www.ncbi.nlm.nih.gov/pubmed/37474720
http://dx.doi.org/10.1038/s41416-023-02349-0

Ejemplares similares